These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33642418)

  • 1. Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk.
    Wang M; Li M; Xie Y
    Endocr J; 2021 Jun; 68(6):729-738. PubMed ID: 33642418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.
    Douros A; Abrahami D; Yin H; Yu OHY; Renoux C; Hudson M; Azoulay L
    Epidemiology; 2018 Nov; 29(6):904-912. PubMed ID: 30028343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
    Charoenngam N; Rittiphairoj T; Ponvilawan B; Ungprasert P
    Diabetes Metab Syndr; 2021; 15(1):249-255. PubMed ID: 33465685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus.
    Zhao L; Meng J; Bai X; Zhang D; Yang X; Yang Y; Cai G; Liu X
    Eur J Med Res; 2024 Jul; 29(1):363. PubMed ID: 38997754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
    Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
    BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
    Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
    Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.
    Radel JA; Pender DN; Shah SA
    Ann Pharmacother; 2019 Jul; 53(7):697-704. PubMed ID: 30700100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Jin Y; Zhao H; Hou Y; Song G
    Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants.
    Li Z; Lin C; Zhou J; Cai X; Zhu X; Hu S; Lv F; Yang W; Ji L
    Expert Opin Investig Drugs; 2022 Sep; 31(9):957-964. PubMed ID: 35968648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
    Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
    J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
    Liu X; Men P; Wang B; Cai G; Zhao Z
    Lipids Health Dis; 2019 Jun; 18(1):144. PubMed ID: 31208420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
    Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
    BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis.
    Morieri ML; Bonora BM; Longato E; Di Camilo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2020 Oct; 22(10):1925-1934. PubMed ID: 32691492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus: A protocol for systematic review and network meta-analysis.
    Yang F; Dong Y; Li B; Ning B; Zhao Q
    Medicine (Baltimore); 2022 Apr; 101(17):e29154. PubMed ID: 35512071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis.
    Guo W; Rathi S; Marquez J; Smith H; Kuruvilla A; Tonnesen MG; Salvemini JN
    Arch Dermatol Res; 2023 Oct; 315(8):2207-2213. PubMed ID: 36867222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
    Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
    Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.